AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

BOSTON, Mass. – September 30, 2024 — Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

CouponFollow Extension

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

BOSTON, Mass. – September 30, 2024 — Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

aktisoncology.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

Sep 30, 2024 · aktis oncology announces $175 million oversubscribed series b financing to further advance its proprietary radiopharmaceutical pipeline Provided by PR Newswire Sep 30, 2024 …

morningstar.com

$175
OFF

Aktis Oncology Unveils $175M Series B Financing To Advance …

4 weeks from now

Sep 30, 2024 · By Karen Roman Aktis Oncology said it raised $175 million in Series B financing, led by RA Capital Management, with RTW Investments and Janus Henderson Investors as co …

yahoo.com

$175
OFF

Aktis Oncology Unveils $175M Series B Financing To Advance …

4 weeks from now

Sep 30, 2024 · Sign up for the latest from Aktis Oncology. Email address: Leave this field empty if you're human: Contact Us

aktisoncology.com

$175
OFF

Radiopharmaceutical Firm Aktis Oncology Raises $175M In Series B …

4 weeks from now

Oct 1, 2024 · Radiology Business

aktisoncology.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

Sep 30, 2024 · Financing led by RA Capital Management and co-led byÂ RTW Investments and Janus Henderson InvestorsProceeds to further advance the company's...

streetinsider.com

$175
OFF

Aktis Oncology Announces $175 Million Oversubscribed Series B …

4 weeks from now

Oct 1, 2024 · BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

biospace.com

$175
OFF

Aktis Raises $175M To Fuel Radiopharma Drug Development

4 weeks from now

Sep 30, 2024 · Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. The Series B round, announced by …

biopharmadive.com

$175
OFF

Aktis Oncology Raises $175M In Series B Funding - Finsmes.com

4 weeks from now

Sep 30, 2024 · Aktis Oncology, a Boston, MA-based clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to …

finsmes.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

BOSTON, Sept. 30, 2024 /PRNewswire/ -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha …

epicos.com

$175
OFF

Big Pharma Backers Return For Aktis' $175M Series B

4 weeks from now

Sep 30, 2024 · Having banked $60 million from Eli Lilly in the spring, Aktis Oncology has now closed an upsized $175 million series B that saw the U.S. Big Pharma rejoin a range of big …

fiercebiotech.com

$175
OFF

Aktis Oncology Closes $175 Million Financing - Aktis

4 weeks from now

Oct 1, 2024 · The Pharma Letter

aktisoncology.com

$175
OFF

Brown Rudnick Assists Aktis Oncology In $175M Series B Financing

4 weeks from now

Sep 30, 2024 · Brown Rudnick acted as corporate and transactional counsel for biotech company Aktis Oncology in its oversubscribed and upsized $175 million Series B financing. Aktis …

brownrudnick.com

$175
OFF

AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED …

4 weeks from now

BOSTON, September 30, 2024-- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to …

vcaonline.com

$175
OFF

T. Rowe Price Funds Join $175M Series B For Aktis Oncology

4 weeks from now

Oct 1, 2024 · T. Rowe Price Funds Join $175M Series B for Aktis Oncology ... CityBiz

aktisoncology.com

FAQs about AKTIS ONCOLOGY ANNOUNCES $175 MILLION OVERSUBSCRIBED … Coupon?

What is aktis oncology doing with $175 million?

JacobH via Getty Images Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. The Series B round, announced by Aktis Monday, was led by RA Capital Management and co-led by RTW Investments and Janus Henderson Investors. ...

How does aktis oncology use actinium 225?

Aktis Oncology uses the radioisotope actinium-225 to develop radiopharmaceutical medicines for cancer. JacobH via Getty Images Boston-based Aktis Oncology has raised $175 million in fresh funding to advance its pipeline of radiopharmaceutical medicines for cancer. ...

Who will join the aktis Oncology board of directors?

In conjunction with the financing, Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management, will join the Aktis Oncology Board of Directors. Lauren Lee, PhD, from RTW Investments, and Vish Sridharan, MD, from Janus Henderson Investors, will join as Observers to the Board of Directors. ...

When will aktis oncology present a presentation?

Aktis Oncology also announced that three abstracts, including one oral presentation, have been accepted for presentation at the upcoming in Barcelona, Spain, October 23-25, 2024. ...

Can Aktis Oncology treat solid tumors?

Aktis Oncology specializes in treating solid tumors using radiopharmaceutical therapies. The company's technology leverages the power of potent alpha radiation to more effectively destroy cancer cells. ...

Who backed aktis?

The Series B round, announced by Aktis Monday, was led by RA Capital Management and co-led by RTW Investments and Janus Henderson Investors. It also drew in pharmas that had previously backed Aktis, namely Bristol Myers Squibb, Eli Lilly and Merck & Co., the latter of which invested via its MRL Ventures Fund. ...